

Real World Studies in Psoriasis in the EU

A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France



NCT03757013

Study type: Observational/Retrospective

A Study of Treatment With Apremilast in Moderate Psoriasis in Real Life Clinical Practice



NCT03059953

Study type: Observational/Prospective

A Study of the Real-life Management of Psoriasis Patients Treated With Apremilast in Belgium



NCT03097003

Study type: Observational/Prospective

A Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain



NCT03539419

Study type: Observational/Prospective

Observational Study of Apremilast in Patients With Psoriasis in The Netherlands



NCT02652494

Study type: Observational/Prospective

Touch map markers for more information on trials

A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice



NCT02740218

Study type: Observational/Retrospective

Apremilast After Fumaric Acid Ester Treatment



NCT02954081

Study type: Observational/Prospective

A Study of Apremilast in Patients With Plaque Psoriasis Under Routine Conditions



NCT02626793

Study type: Observational/Prospective

A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice



NCT04031027

Study type: Observational/Retrospective

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017

Psoriasis

Plaque Psoriasis

Moderate Plaque Psoriasis



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

Study type: Observational/Retrospective



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis

Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of the Real-life Management of Psoriasis Patients
Treated With Apremilast in Belgium



NCT03097003

Study type: Observational/Prospective

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become
commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis



Real World Studies in Psoriasis in the EU


A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France



NCT03757013

Study type: Observational/Retrospective

Touch map markers for
more information on trials



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

Apremilast After Fumaric Acid Ester Treatment

APARTTM
Apremilast / fumaryl Acid Ester Treatment

NCT02954081

Study type: Observational/Prospective

A Study of Apremilast in Patients With Plaque Psoriasis
Under Routine Conditions

LAPIS-PsoTM

NCT02626793

Study type: Observational/Prospective

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis

Celgene

Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

Study type: Observational/Retrospective



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis

Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Treatment With Apremilast in Moderate
Psoriasis in Real Life Clinical Practice



NCT03059953

Study type: Observational/Prospective



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

Study type: Observational/Retrospective



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis

Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials



Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


Celgene Corporation 9/19 NP-GII-OTZ-0017



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

A Study to Evaluate the Benefits for the Patient
Associated With the Treatment of Plaque Psoriasis With
Apremilast After Other Systemic Treatment in Conditions
of Clinical Practice in Spain



NCT03539419

Study type: Observational/Prospective

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become
commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218



Psoriasis



Plaque
Psoriasis



Moderate
Plaque Psoriasis

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become

commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017



Real World Studies in Psoriasis in the EU



Touch map markers for
more information on trials

A Study of Real-World Experience of Psoriasis Patients
Treated With Apremilast in Clinical Dermatology Practice

APPRECIATETM
APREmilast Clinical Treatment Experience
in psoriasis

NCT02740218

Moderate
Plaque Psoriasis

Psoriasis

Plaque
Psoriasis

Data pulled from ClinicalTrials.gov as of September 12, 2019.

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no guarantee that the agents will receive health authority approval or become
commercially available in any country for the uses being investigated.

Celgene Corporation 9/19 NP-GII-OTZ-0017

Celgene